LAGUNA NIGUEL, Calif., July 2, 2024 /PRNewswire/ — Alleva, a premier provider of electronic medical record (EMR) software solutions tailored for the behavioral health and addiction recovery sectors, is proud to announce its inclusion in the Software Advice FrontRunners for HIPAA Compliance Software report for 2024. This prestigious recognition is based on reviews from real software users, highlighting Alleva as one of the top-rated HIPAA Compliance Software products in North America.
“We are honored to be featured in the Software Advice FrontRunners report,” said Steven McCall, CEO of Alleva. “This badge is a testament to our commitment to delivering high-quality technology that empowers healthcare professionals to provide exceptional care. It also reinforces our credibility and reliability in the market, encouraging more behavioral health clinics and caretakers to trust our solutions.”
Benefits of Alleva’s EMR Software Solutions:
The recognition by Software Advice, coupled with the badge on Alleva’s website, serves as a significant milestone in the company’s journey to support healthcare professionals in delivering premium care. To learn more about Alleva’s solutions or to schedule a demo, healthcare providers and caretakers are encouraged to visit their website.
About Alleva
Alleva is a leading provider of EMR software solutions designed specifically for the behavioral health and addiction recovery sectors. By leveraging cutting-edge technology, Alleva aims to deliver premium care to those in need and support healthcare professionals with comprehensive, reliable, and secure software tools.
Media Contact:
Sheena Streling
sheena.streling@helloalleva.com
SOURCE Alleva
The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have…
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology…
Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with ≥3 prior lines…
- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92%…
Media ReleaseCOPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab…
― Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at…